Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
IPO News

| More

Emcure Pharmaceuticals Limited files DRHP for an IPO

Posted On: 2013-07-01 22:56:27

Emcure Pharmaceuticals Limited (the "Company" or the "Issuer") has filed a draft red herring prospectus (the "DRHP") with the Securities and Exchange Board of India ("SEBI") for offering of equity shares of face value Rs. 10 each (the "Equity Shares") for cash at a price per Equity Share including a share premium to be determined through the book building process (the "Issue"). The Issue comprises a fresh issue of Equity Shares aggregating up to Rs. 3,000 million (the "Fresh Issue") and an offer for sale of up to 2,513,057 Equity Shares by certain existing shareholders of the Company.

In terms of Rule 19(2)(b)(ii) of the Securities Contracts (Regulation) Rules, 1957, as amended (the "SCRR"), the Issue is for at least 10% of the post-Issue capital where the post-Issue capital of the Company calculated at the Issue Price will be more than Rs. 40,000 million. Not more than 50% of the Issue shall be available for allocation on a proportionate basis to qualified institutional buyer ("QIB") bidders; 5% of the QIB Portion (excluding anchor investor portion) shall be available for allocation on a proportionate basis to mutual funds only, and the remainder of the QIB portion shall be available for allocation on a proportionate basis to all QIBs, including mutual funds, subject to valid bids being received at or above the Issue price. Further, not less than 15% of the Issue shall be available for allocation on a proportionate basis to non-institutional bidders and not less than 35% of the Issue shall be available for allocation to retail individual bidders, subject to valid bids being received at or above the Issue price. QIBs (other than anchor investors) and non-institutional bidders shall participate in the Issue through the application supported by blocked amount ("ASBA") process only providing the details of the bank account which will be blocked by the self certified syndicate banks to the extent of the bid amount for the same. Retail individual bidders may also participate in the Issue through the ASBA process.

The Equity Shares offered in the Issue are proposed to be listed on BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE").

The book running lead managers to the Issue are DSP Merrill Lynch Limited, IDFC Capital Limited and Morgan Stanley India Company Private Limited.

The Company is a fast growing Indian pharmaceutical company engaged in developing, manufacturing and marketing a broad range of pharmaceutical products globally. Its core strength lies in in-house development and manufacturing of differentiated pharmaceutical products. The Company focuses its research and development efforts on developing a portfolio of differentiated products across several platforms, including chiral molecules, biosimilars and novel drug delivery systems. The Company commercializes its products through a combination of its own marketing and distribution infrastructure across geographies as well as relationships with multi-national pharmaceutical companies.

The Company believes its competitive advantage in the domestic market lies in its established presence in all major therapeutic areas. It has a pan India marketing and distribution presence with a field force of more than 4,800 personnel, as of March 31, 2013. The Company has a well-diversified income base in terms of geographies, therapeutic areas and business segments within the pharmaceutical industry. The Company has its own sales and marketing infrastructure in the United States through its subsidiary, Heritage. The Company also sells its portfolio of branded generic products to the rest of world. Its products are currently shipped to over 65 countries, where it has established its presence by focusing on important alliances with local and multi-national companies. The Company has subsidiaries in Brazil, Dubai, Nigeria, Singapore and South Africa and branch offices in Morocco and Russia, which play an important role in its international operations. It operates nine manufacturing facilities, eight of which are located in India and one in the United States. Several of these facilities have approvals from various regulatory bodies, including the USFDA and the UK-MHRA. These facilities are capable of producing APIs and pharmaceutical products encompassing a wide range of dosage forms including oral solids, oral liquids, soft gelatin capsules and injectables (both liquid and lyophilized). The manufacturing capability of the Company allows it to manufacture complex products, including cytotoxic products. The Company also manufactures products for certain pharmaceutical multi-national companies and the Company believes that it has emerged as a technologically dependable and quality conscious company of choice for these companies. The Company is led by highly qualified and experienced management team and the board of directors.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Indian Energy Exchange to list on Oct 23, 2017
Mahindra Logistics Limited IPO to open for subscription on Oct 31, 2017
Reliance Nippon Life Asset Management Limited's IPO to open on Wednesday, October 25, 2017
IPO Note - General Insurance Corporation of India (GIC Re): Angel Broking
General Insurance Corporation Of India - IPO Note - Arihant Capital Markets
Indian Energy Exchange - IPO Note - Angel Broking
Indian Energy Exchange Limited IPO to open for subscription on Oct 9, 2017
MAS Financials Services Ltd - On the track to excel - Angel Broking
General Insurance Corporation Of India's IPO to hit markets on Oct 11, 2017
Godrej Agrovet Limited IPO receives huge response with subscription of 90.18 times till 3:45 PM
Godrej Agrovet Limited IPO receives subscription of 33.27 times till 2:30 PM
Godrej Agrovet Limited IPO receives subscription of 4.42 times till 12:00 noon
IPO Note - MAS Financials Services Ltd: Angel Broking
Prataap Snacks Ltd to list today
IPO Note - Godrej Agrovet Limited: Angel Broking
SBI Life Insurance Company Limited to list on Oct 3, 2017
Godrej Agrovet Limited - IPO Note - Sushil Finance
MAS Financial Services Ltd's IPO to open on Oct 6, 2017
Godrej Agrovet Limited fixes IPO price band as Rs. 450 to Rs. 460
SBI Life Insurance Company Limited IPO gets subscription of 3.58 times
Godrej Agrovet Ltd IPO to hit markets on Oct 4, 2017
ICICI Lombard General Insurance Company Limited IPO receives subscription of 2.98 times
Prataap Snacks Limited - IPO Note - Angel Broking
SBI Life Insurance Co Ltd - IPO Note - Angel Broking
Matrimony.com Limited to list on Sep 21, 2017
SBI Life Insurance Company Limited IPO to hit markets on Sep 20, 2017
ICICI Lombard General Insurance Company Limited IPO to close on Sep 19, 2017
Capacit'e Infraprojects Limited IPO receives overwhelming response
Matrimony.com Limited IPO receives subscription of 4.44 times
ICICI Lombard General Insurance Company Ltd - IPO Note - Angel Broking
Capacit'e Infra projects Ltd - IPO Note - Capacit'e for towering growth - Angel Broking
Matrimony.com - IPO Note - Arihant Capital Markets
Capacit'e Infraprojects Ltd - Healthy order book with strong execution... - Geojit
Capacit'e Infraprojects Limited IPO to open for subscription on Sep 13, 2017
Matrimony.com Limited IPO to open for subscription on Sep 11, 2017
Bharat Road Network Limited IPO subscribed 1.81 times
Dixon Technologies India Limited IPO receives subscription of 117.83 times
Matrimony.com - IPO Note - Angel Broking
ICICI Lombard's IPO to hit markets on Sep 15, 2017
Bharat Road Network Ltd - IPO Note - Angel Broking
Dixon Technologies India Ltd - IPO Note - The trajectory of strong client base continues - Angel Broking
IRDAI grants in-principle approval for Reliance General Insurance IPO
Dixon Technology IPO to open for subscription on Sep 6, 2017 - Sushil Finance
Future Enterprises Ltd to divest stake in Future Supply Chain Solutions Ltd through IPO
Bharat Road Network Limited IPO to hit markets on Sep 6, 2017
HDFC updates on proposed IPO of HDFC Standard Life Insurance Company Ltd
Srei Equipment Finance plans to dilute upto 25% of its capital
Cochin Shipyard Ltd - IPO Note - Angel Broking
Security and Intelligence Services (India) Ltd - IPO Note - Angel Broking
M&M to sell part of its stake in Mahindra Logistics Ltd in IPO


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2017